Navigation Links
Dependence in Biological Technology

Human Genome Sciences Announces Closing of Public Offering

... Genome Sciences' unproven business model, its dependence on new technologies, the uncertainty and timing ... to develop and commercialize products, its dependence on collaborators for services and revenue, its ... property protection, Human Genome Sciences' dependence on key management and key suppliers, the ...

Endo Pharmaceuticals Reports Strong Second Quarter 2009 Financial Results

... regulation of the pharmaceutical industry; our dependence on a small number of products and on outside manufacturers for the manufacture of our products; our dependence on third parties to supply raw materials and to ... litigation or claims by the government; our dependence on sales to a limited number of large pharmacy ...

Neurocrine Biosciences Reports Second Quarter 2009 Results

... trials; and risks associated with the Company's dependence on corporate collaborators for development, ... candidates; risk relating to the Company's dependence on contract manufacturers for clinical drug supply; risks associated with the Company's dependence on corporate collaborators for commercial ...

Elagolix Successful in Six Month Lilac Petal Study; Safety and Efficacy Confirmed in Patients With Endometriosis

... trials; risk associated with the Company's dependence on corporate collaborators for development, ... candidates; risk relating to the Company's dependence on contract manufacturers for clinical drug supply; risks associated with the Company's dependence on corporate collaborators for commercial ...

Human Genome Sciences Announces Pricing of Public Offering of Common Stock

... Genome Sciences' unproven business model, its dependence on new technologies, the uncertainty and timing ... to develop and commercialize products, its dependence on collaborators for services and revenue, its ... property protection, Human Genome Sciences' dependence on key management and key suppliers, the ...

Human Genome Sciences Announces Proposed Public Offering of Common Stock

... Genome Sciences' unproven business model, its dependence on new technologies, the uncertainty and timing ... to develop and commercialize products, its dependence on collaborators for services and revenue, its ... property protection, Human Genome Sciences' dependence on key management and key suppliers, the ...

Human Genome Sciences Announces New Order for Raxibacumab (ABthrax(TM)) from U.S. Government

... of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing ... to develop and commercialize products, its dependence on collaborators for services and revenue, its ... intellectual property protection, the Company's dependence on key management and key suppliers, the ...

Studies Presented at International Conference on Alzheimer's Disease Reveal Substantial Economic Costs and Caregiver Burden Associated with Alzheimer's Disease

... #P3-221: Predicting Costs of Care for Unique dependence Levels in Patients with AD (Murman DL, et al.) ... relationship between total costs and AD dependence levels, with costs increasing significantly with increasing dependence. In this study, dependence level provided a useful method to estimate unique ...

Data Published in The New England Journal of Medicine Support Use of Raxibacumab (ABthrax(TM)) for the Treatment of Inhalation Anthrax

... of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing ... to develop and commercialize products, its dependence on collaborators for services and revenue, its ... intellectual property protection, the Company's dependence on key management and key suppliers, the ...

Human Genome Sciences to Host July 20 Conference Call to Discuss Top-Line Phase 3 Results for Benlysta(TM) (Formerly Lymphostat-B(R)) in Systemic Lupus Erythematosus

... of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing ... to develop and commercialize products, its dependence on collaborators for services and revenue, its ... intellectual property protection, the Company's dependence on key management and key suppliers, the ...

Human Genome Sciences Announces Completion of Enrollment in Phase 2b Monthly-Dosing Trial of Albuferon(R)

... of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing ... to develop and commercialize products, its dependence on collaborators for services and revenue, its ... intellectual property protection, the Company's dependence on key management and key suppliers, the ...

Helix BioPharma Announces Q3 2009 Financial Results and Provides Product Development Update

... market opportunity for Helix's products; Helix's dependence on its contractors, consultants, advisors and ... the drug candidate and on the Company; Helix's dependence on its licensor of the L-DOS47 antibody; the need ... which may arise out of DOS47; the Company's dependence on a few customers and a few suppliers, the loss ...

Human Genome Sciences Reports Positive Long-Term Data for BENLYSTA(TM) (Formerly LymphoStat-B(R)) in Patients With Active Systemic Lupus Erythematosus

... of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing ... to develop and commercialize products, its dependence on collaborators for services and revenue, its ... intellectual property protection, the Company's dependence on key management and key suppliers, the ...

DuPont Innovation Addressing Major Global Market Trends

... in Increasing Food Productivity, Decreasing dependence on Fossil Fuels, Protecting Lives, Growing in ... for increasing food productivity, decreasing dependence on fossil fuels, protecting lives and growing in ... of increasing food productivity, decreasing dependence on fossil fuels and protecting lives. With ...

Human Genome Sciences and Novozymes Announce Amendment to Albumin Fusion License Agreement

... of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing ... to develop and commercialize products, its dependence on collaborators for services and revenue, its ... intellectual property protection, the Company's dependence on key management and key suppliers, the ...

Neurocrine Biosciences Reports First Quarter 2009 Results

... trials; risks associated with the Company's dependence on corporate collaborators for development, ... candidates; risk relating to the Company's dependence on contract manufacturers for clinical drug supply; risks associated with the Company's dependence on corporate collaborators for commercial ...

Human Genome Sciences Announces First Quarter 2009 Financial Results and Key Developments

... of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing ... to develop and commercialize products, its dependence on collaborators for services and revenue, its ... intellectual property protection, the Company's dependence on key management and key suppliers, the ...

Human Genome Sciences to Sponsor Conference Call to Discuss First Quarter 2009 Financial Results

... of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing ... to develop and commercialize products, its dependence on collaborators for services and revenue, its ... intellectual property protection, the Company's dependence on key management and key suppliers, the ...

Endo Pharmaceuticals Appoints Dr. Nancy Hutson to Board of Directors

... regulation of the pharmaceutical industry; our dependence on a small number of products and on outside manufacturers for the manufacture of our products; our dependence on third parties to supply raw materials and to ... litigation or claims by the government; our dependence on sales to a limited number of large pharmacy ...

Human Genome Sciences and Morphotek(R), Inc. Announce Collaboration to Discover, Develop and Commercialize Antibodies for Oncology and Immunology

... of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing ... to develop and commercialize products, its dependence on collaborators for services and revenue, its ... intellectual property protection, the Company's dependence on key management and key suppliers, the ...

Human Genome Sciences to Sponsor Conference Call

... of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing ... to develop and commercialize products, its dependence on collaborators for services and revenue, its ... intellectual property protection, the Company's dependence on key management and key suppliers, the ...

Human Genome Sciences to Sponsor Conference Call to Discuss Full Year 2008 Financial Results

... of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing ... to develop and commercialize products, its dependence on collaborators for services and revenue, its ... intellectual property protection, the Company's dependence on key management and key suppliers, the ...

Human Genome Sciences to Receive $9 Million Milestone Payment Related to GlaxoSmithKline Initiation of Phase 3 Clinical Trial of Syncria(R) in Type 2 Diabetes

... of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing ... to develop and commercialize products, its dependence on collaborators for services and revenue, its ... intellectual property protection, the Company's dependence on key management and key suppliers, the ...

Human Genome Sciences Announces Initiation of Phase 2b Trial of Albuferon(R) Dosed Monthly in Chronic Hepatitis C

... of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing ... to develop and commercialize products, its dependence on collaborators for services and revenue, its ... intellectual property protection, the Company's dependence on key management and key suppliers, the ...

Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C

... of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing ... to develop and commercialize products, its dependence on collaborators for services and revenue, its ... intellectual property protection, the Company's dependence on key management and key suppliers, the ...

Human Genome Sciences Announces Third Quarter 2008 Financial Results and Key Developments

... of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing ... to develop and commercialize products, its dependence on collaborators for services and revenue, ... intellectual property protection, the Company's dependence on key management and key suppliers, the ...

Human Genome Sciences to Sponsor Conference Call to Discuss Third Quarter 2008 Financial Results

... of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing ... to develop and commercialize products, its dependence on collaborators for services and revenue, ... intellectual property protection, the Company's dependence on key management and key suppliers, the ...

Human Genome Sciences Announces Process Development and Manufacturing Alliance With Hospira

... of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing ... to develop and commercialize products, its dependence on collaborators for services and revenue, ... intellectual property protection, the Company's dependence on key management and key suppliers, the ...

Human Genome Sciences Announces Second Quarter 2008 Financial Results and Key Developments

... of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing ... to develop and commercialize products, its dependence on collaborators for services and revenue, ... intellectual property protection, the Company's dependence on key management and key suppliers, the ...

Indevus Pharmaceuticals to Announce Third Quarter Fiscal 2008 Financial Results on August 5, 2008

... elsewhere, and include, but are not limited to: dependence on the success of SANCTURA, SANCTURA XR, NEBIDO, ... spending, third-party relationships and revenues; dependence on third parties for supplies, particularly ... having limited patents and proprietary rights; dependence on market exclusivity, changes in reimbursement ...

Human Genome Sciences Appoints David P. Southwell to its Board of Directors

... of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing ... to develop and commercialize products, its dependence on collaborators for services and revenue, ... intellectual property protection, the Company's dependence on key management and key suppliers, the ...

Human Genome Sciences to Sponsor Conference Call to Discuss Second Quarter 2008 Financial Results

... of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing ... to develop and commercialize products, its dependence on collaborators for services and revenue, ... intellectual property protection, the Company's dependence on key management and key suppliers, the ...

ViroPharma To Acquire Lev Pharmaceuticals

... a biologics license has been applied, our heavy dependence on the success of Cinryze(TM), our dependence on our suppliers, our dependence on third parties to manufacture Cinryze(TM), ...

Indevus Receives Approvable Letter from FDA for NEBIDO(R)

... elsewhere, and include, but are not limited to: dependence on the success of SANCTURA, SANCTURA XR, NEBIDO, ... spending, third-party relationships and revenues; dependence on third parties for supplies, particularly ... having limited patents and proprietary rights; dependence on market exclusivity, changes in reimbursement ...

Indevus Announces Management Changes

... elsewhere, and include, but are not limited to: dependence on the success of SANCTURA, SANCTURA XR, NEBIDO, ... spending, third-party relationships and revenues; dependence on third parties for supplies, particularly ... having limited patents and proprietary rights; dependence on market exclusivity, changes in reimbursement ...

Indevus Pharmaceuticals Scheduled to Present at Upcoming Investor Conferences

... elsewhere, and include, but are not limited to: dependence on the success of SANCTURA, SANCTURA XR, NEBIDO, ... spending, third-party relationships and revenues; dependence on third parties for supplies, particularly ... having limited patents and proprietary rights; dependence on market exclusivity, changes in reimbursement ...

Human Genome Sciences Names Kevin P. McRaith Vice President, Hepatology Franchise

... of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing ... to develop and commercialize products, its dependence on collaborators for services and revenue, ... intellectual property protection, the Company's dependence on key management and key suppliers, the ...

Two Year Study Confirms SUPPRELIN(R) LA Implant Maintains Profound Suppression of Hormones in Children With Premature Onset Puberty

... elsewhere, and include, but are not limited to: dependence on the success of SANCTURA, SANCTURA XR, NEBIDO, ... spending, third-party relationships and revenues; dependence on third parties for supplies, particularly ... having limited patents and proprietary rights; dependence on market exclusivity, changes in reimbursement ...

Human Genome Sciences Announces First Quarter 2008 Financial Results and Key Developments

... of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing ... to develop and commercialize products, its dependence on collaborators for services and revenue, ... intellectual property protection, the Company's dependence on key management and key suppliers, the ...

Human Genome Sciences to Sponsor Conference Call to Discuss First Quarter 2008 Financial Results

... of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing ... to develop and commercialize products, its dependence on collaborators for services and revenue, ... intellectual property protection, the Company's dependence on key management and key suppliers, the ...
Other Contents
(Date:7/31/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market and creator of the Wocket® ... 62/198989 for ELECTRONIC CRYPTO-CURRENCY MANAGEMENT METHOD AND ... advance crypto-currencies such as Bitcoin into the consumer market ... to manage all payments.  The technology ...
(Date:7/23/2015)... BEDFORD, Mass., July 23, 2015 Aware, Inc. (NASDAQ: ... services, today reported financial results for its second quarter ended ... quarter of 2015 was $4.5 million, a decrease of 33% ...  Net income in the second quarter of 2015 was $0.3 ... million, or $0.04 per diluted share, in the same period ...
(Date:7/20/2015)... , July 20, 2015  Acuity Market Intelligence,s ... The Convergence of Commerce and Privacy" forecasts that ... biometric apps will be downloaded to smart mobile ... mobile biometrics market is projected to generate more ... during the seven-year forecast period.    ...
Breaking Biology News(10 mins):NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... ... finalist in 2015 MarketingProfs Bright Bulb B2B Awards. , The MarketingProfs Bright Bulb ... for B2B brands. BESLER Consulting's campaign for the launch of their Readmissions Analytics ...
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... ... technologies and development solutions for drugs, biologics and consumer health products, today welcomed ... accepted for review OPKO’s New Drug Application for a new treatment for chronic ...
(Date:8/3/2015)... ... ... The art of preparing and cooking food comes naturally to some. For ... Nasreen Zereshki was extremely eager to cook Persian cuisine. Now that she is skilled ... Kitchen with the world. , Since Americans tend to be undereducated about Persian cuisine, ...
(Date:8/3/2015)... ... ... The U.S. Food and Drug Administration (FDA) recently approved a new non-invasive treatment ... naturally in the body and helps absorb and breakdown fat cells. Previously, plastic surgery ... are invasive procedures and very expensive for most people. Now with Kybella, there is ...
(Date:8/3/2015)... ... ... Dignity Health named Dr. Norris A. Baldwin, Jr. the Facility Medical Director ... August. The new facility is licensed under Dignity Health Arizona General Hospital ... is an excellent leader and will ensure our new freestanding emergency room delivers the ...
Breaking Medicine News(10 mins):Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 2Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 3Health News:Persian Cuisine: Colorful and Extremely Healthy 2Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 2Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 3Health News:Dignity Health Names Dr. Norris A. Baldwin, Jr. Facility Medical Director of New Freestanding Emergency Room 2Health News:Dignity Health Names Dr. Norris A. Baldwin, Jr. Facility Medical Director of New Freestanding Emergency Room 3
Other TagsOther Tags